Drugs / Capsaicin
Capsaicin
also known as
QUTENZA · NGX-4010 · ALGRX 4975 · CNTX-4975 · 4975 · NGX-1998 · Zostrix · 8-methyl-N-vanillyl-6-nonenamide · +8 more
Small molecule targets TRPV1 via activation
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | QUTENZA | — | 2020-07-17 | fda.gov ↗ |
| Approved | US (FDA) | QUTENZA | — | 2009-11-16 | fda.gov ↗ |
| Approved | EU (EMA) | Qutenza | — | 2009-05-15 | europa.eu ↗ |
Trials 111 · started per year
today
EU approved 2009
US approved 2009
1
1
1
1
1
4
7
3
4
4
5
5
5
4
3
4
5
6
4
8
2
7
5
5
3
4
2
1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials · 1 missed | ||||||
| Phase 0 | NCT06744816 | Dec 2025 → Nov 2027 expected | chemotherapy-induced neuropathy | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 0 | NCT06444594 | Jul 2024 → Dec 2025 overdue | premature aging syndrome | Penn State University | Recruiting | No outcome recorded |
| Phase 0 | NCT05649228 | Dec 2022 → Jan 2024 | — | Carilion Clinic | Completed | No outcome recorded |
| Phase 0 | NCT04256733 | May 2019 → Nov 2020 | — | University of Montana | Completed | Missed primary |
| Phase 0 | NCT02240329 | Mar 2013 → Jun 2015 | traumatic brain injury | University of Florida | Completed | No outcome recorded |
| Phase 110 trials · 2 missed | ||||||
| Phase 1 | NCT06614608 | Oct 2024 → Apr 2025 overdue | osteoarthritis, knee | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06809569 | Sep → Dec 2023 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT05226299 | May 2021 → May 2022 | — | University of Montana | Completed | Missed primary |
| Phase 1 | NCT04545892 | Dec 2019 → Jul 2020 | stroke disorder | Juan Manuel Marquez Romero | Completed | No outcome recorded |
| Phase 1 | NCT03899246 | Jul 2019 → Mar 2020 | neuropathy, painful, sickle cell disease | Children's Hospital of Michigan | Completed | No outcome recorded |
| Phase 1 | NCT03511846 | Mar 2018 → May 2028 expected | SUNCT syndrome, cluster headache syndrome, hemicrania continua, migraine disorder +1 | The University of Texas Health Science Center, Houston | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT03074162 | Apr → Jun 2017 | — | Boehringer Ingelheim | Completed | Missed primary |
| Phase 1 | NCT01883102 | Jun 2013 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00254449 | Nov 2005 → May 2006 | — | NeurogesX | Completed | No outcome recorded |
| Phase 1 | NCT00528216 | — | — | NeurogesX | Completed | No outcome recorded |
| Phase 1/26 trials · 1 met primary | ||||||
| Phase 1/2 | NCT03122145 | May 2017 → Feb 2019 | — | University of Florida | Completed | No outcome recorded |
| Phase 1/2 | NCT02769910 | May → Jul 2016 | — | Hjalte Holm Andersen | Completed | No outcome recorded |
| Phase 1/2 | NCT02183519 | Oct 2014 → Aug 2015 | Parkinson disease | University of Florida | Completed | No outcome recorded |
| Phase 1/2 | NCT01907321 | Jan 2011 → Apr 2015 | ischemic stroke | University of Florida | Completed | Met primary |
| Phase 1/2 | NCT02228928 | Feb 2009 → May 2011 | peripheral nerve lesion, postherpetic neuralgia | Samyang Biopharmaceuticals Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT00004316 | Jun 1995 → Aug 2007 | interstitial cystitis, vulvar disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 231 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT07406971 | Sep 2025 → Sep 2026 overdue | ischemic stroke | Mexican Social Security Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT05543837 | Sep 2022 | cerebrovascular disorder | Mexican Social Security Institute | Completed | No outcome recorded |
| Phase 2 | NCT05098067 | May → Oct 2022 | hyperemesis gravidarum | Women and Infants Hospital of Rhode Island | Completed | Missed primary |
| Phase 2 | NCT04470752 | Aug 2021 → Dec 2024 | — | Georg Kägi, MD | Unknown | No outcome recorded |
| Phase 2 | NCT04972123 | Jul 2021 → Aug 2023 | syncope, familial vasovagal | University of Wisconsin, Madison | Completed | Missed primary |
| Phase 2 | NCT04704453 | Apr 2021 → Apr 2025 | head and neck cancer | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 2 | NCT04918069 | Oct 2019 → May 2022 | chemotherapy-induced toxicity | Christian Medical College, Vellore, India | Completed | No outcome recorded |
| Phase 2 | NCT03528369 | May → Oct 2018 | osteoarthritis, knee | Propella Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03223350 | Dec 2017 → Aug 2019 | cyclic vomiting syndrome | Henry Ford Health System | Completed | No outcome recorded |
| Phase 2 | NCT03317613 | Nov 2017 → Dec 2020 | neuropathy, painful | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 2 | NCT02678793 | Dec 2015 → Dec 2016 | Morton neuroma | Centrexion Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02558439 | Aug 2015 → Oct 2016 | osteoarthritis | Centrexion Therapeutics | Completed | Met primary |
| Phase 2 | NCT02493257 | Oct 2014 → Aug 2019 | rhinitis | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2 | NCT02283957 | Oct 2014 → Aug 2015 | Morton neuroma | Centrexion Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01260454 | Nov 2010 → Dec 2011 | pulmonary arterial hypertension | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT01228838 | Oct 2010 → Sep 2011 | postherpetic neuralgia | NeurogesX | Completed | No outcome recorded |
| Phase 2 | NCT00916942 | Jun 2009 | postherpetic neuralgia | NeurogesX | Completed | No outcome recorded |
| Phase 2 | NCT00683267 | Sep 2007 → Nov 2008 | — | Anesiva, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00667654 | Aug 2007 → Jun 2008 | osteoarthritis, knee | Centrexion Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00146198 | Sep 2005 → Feb 2006 | — | AlgoRx Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00233155 | Aug 2005 → Dec 2006 | HIV infectious disease, herpes zoster, neuralgia | NeurogesX | Completed | No outcome recorded |
| Phase 2 | NCT00133133 | Jul → Dec 2005 | — | AlgoRx Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00132392 | Jul → Dec 2005 | — | AlgoRx Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00130949 | Nov 2004 → Nov 2005 | epicondylitis | AlgoRx Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00130962 | Sep 2004 → Feb 2006 | neuroma | AlgoRx Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00088686 | Jul 2004 → Oct 2005 | — | National Institute of Dental and Craniofacial Research (NIDCR) | Completed | No outcome recorded |
| Phase 2 | NCT00034710 | Mar → Oct 2002 | herpes zoster, neuralgia | NeurogesX | Completed | No outcome recorded |
| Phase 2 | NCT00008476 | Jan 2001 → Jan 2004 | — | National Institute of Dental and Craniofacial Research (NIDCR) | Completed | No outcome recorded |
| Phase 2 | NCT00089557 | — | HIV infectious disease, diabetes mellitus, diabetic neuropathy, herpes zoster +2 | NeurogesX | Terminated | No outcome recorded |
| Phase 2 | NCT00061152 | — | HIV infectious disease | NeurogesX | Unknown | No outcome recorded |
| Phase 2 | NCT00082316 | — | HIV infectious disease, diabetes mellitus, diabetic neuropathy, herpes zoster +2 | NeurogesX | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT02823912 | Oct 2016 → Apr 2017 | hyperlipidemia, obesity disorder | University of Guadalajara | Unknown | No outcome recorded |
| Phase 2/3 | NCT02854670 | Jan 2016 → Feb 2021 | vulvodynia | Centre Hospitalier Universitaire de Besancon | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT00993070 | Oct 2009 → Dec 2011 | diabetic polyneuropathy | Thammasat University | Completed | No outcome recorded |
| Phase 2/3 | NCT01125215 | Sep 2009 → Oct 2013 | neuropathy, painful | Mahidol University | Unknown | No outcome recorded |
| Phase 2/3 | NCT00302263 | Jan → Apr 2005 | obesity disorder | University of Copenhagen | Completed | No outcome recorded |
| Phase 2/3 | NCT00302276 | Jan → Jul 2004 | obesity disorder | University of Copenhagen | Completed | No outcome recorded |
| Phase 2/3 | NCT00061776 | — | herpes zoster, neuralgia | NeurogesX | Completed | No outcome recorded |
| Phase 318 trials · 5 met primary · 3 missed | ||||||
| Phase 3 | NCT06023706 | Nov 2023 → May 2027 expected | coccygodynia, neuropathy, painful | Nantes University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05840562 | Oct 2023 → Mar 2028 expected | chemotherapy-induced neuropathy | Institut Cancerologie de l'Ouest | Recruiting | No outcome recorded |
| Phase 3 | NCT04967664 | Jul 2021 → Aug 2025 | neuropathy, painful | Averitas Pharma, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05093478 | Sep 2019 → Nov 2023 | rhinitis | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 3 | NCT03794388 | Mar 2019 → Nov 2022 | female breast carcinoma | Institut Cancerologie de l'Ouest | Completed | No outcome recorded |
| Phase 3 | NCT02700815 | May 2016 → Jul 2017 | — | Boehringer Ingelheim | Completed | Met primary |
| Phase 3 | NCT03153813 | Jul 2015 → Dec 2017 | — | Nadine ATTAL | Terminated | No outcome recorded |
| Phase 3 | NCT01533428 | Feb 2012 → Feb 2014 | diabetic polyneuropathy | Astellas Pharma Inc | Completed | Met primary |
| Phase 3 | NCT01478607 | Nov 2011 → Feb 2014 | diabetic polyneuropathy | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT05029297 | Nov 2010 → Oct 2018 | diabetic neuropathy | Arafarma Group, S.A. | Completed | No outcome recorded |
| Phase 3 | NCT00681356 | Sep 2007 → Sep 2008 | — | Anesiva, Inc. | Completed | Missed primary |
| Phase 3 | NCT00471055 | Jun → Oct 2007 | osteoarthritis, knee | Khon Kaen University | Completed | No outcome recorded |
| Phase 3 | NCT00321672 | Jun 2006 → Dec 2007 | HIV infectious disease, peripheral neuropathy | NeurogesX | Completed | Missed primary |
| Phase 3 | NCT00300222 | Mar 2006 → Aug 2007 | herpes zoster, neuralgia | NeurogesX | Completed | Met primary |
| Phase 3 | NCT00115310 | Jun 2005 → Oct 2006 | herpes zoster, neuralgia | NeurogesX | Completed | Met primary |
| Phase 3 | NCT00064623 | Aug 2003 → Nov 2005 | HIV infectious disease, peripheral neuropathy | NeurogesX | Completed | Met primary |
| Phase 3 | NCT00068081 | — | herpes zoster, neuralgia | NeurogesX | Completed | Missed primary |
| Phase 3 | NCT00085761 | — | HIV infectious disease, peripheral nervous system disorder | NeurogesX | Terminated | No outcome recorded |
| Phase 417 trials · 1 met primary | ||||||
| Phase 4 | NCT07795593 | Oct 2026 → May 2031 expected | diabetic kidney disease, diabetic neuropathy | University of Michigan | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06444919 | Mar 2025 → Jan 2028 expected | neuropathy, painful, osteoarthritis, hand | University Hospital, Clermont-Ferrand | Recruiting | No outcome recorded |
| Phase 4 | NCT06040190 | Nov 2023 → Jul 2026 overdue | burning mouth syndrome | Federal University of Minas Gerais | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05298202 | May → Oct 2022 | — | University of Nebraska | Completed | Mixed |
| Phase 4 | NCT04283292 | Dec 2020 → Mar 2022 | cannabinoid hyperemesis syndrome | University of Virginia | Completed | No outcome recorded |
| Phase 4 | NCT04238208 | Jan → Dec 2019 | diabetic polyneuropathy | Corporacion Parc Tauli | Completed | No outcome recorded |
| Phase 4 | NCT03348735 | Dec 2018 → Apr 2021 | neuropathy, painful | University Hospital, Antwerp | Terminated | No outcome recorded |
| Phase 4 | NCT02288156 | Jul 2015 → Dec 2018 | rhinitis | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT01704339 | Dec 2012 → Dec 2013 | end stage renal failure, neuropathy, painful | Emma Aitken | Unknown | No outcome recorded |
| Phase 4 | NCT01713426 | Jul 2012 → Sep 2013 | neuropathy, painful, postherpetic neuralgia, traumatic neuropathy | Astellas Pharma Europe Ltd. | Completed | Met primary |
| Phase 4 | NCT01862523 | Feb 2012 → Dec 2014 | rhinitis | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT01416116 | Jul 2011 → Apr 2012 | peripheral nerve lesion, postherpetic neuralgia | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT01223820 | Jan → Sep 2011 | rhinitis | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT01252160 | Oct 2010 → Sep 2013 | postherpetic neuralgia | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT00771511 | Oct 2010 → Jun 2011 | pregnancy disorder with abortive outcome | Columbia University | Withdrawn | No outcome recorded |
| Phase 4 | NCT00697034 | Jun 2006 → Aug 2007 | psoriasis | Wake Forest University | Terminated | No outcome recorded |
| Phase 4 | NCT00176969 | Aug 1997 → Jun 2000 | alopecia areata | University of Minnesota | Completed | No outcome recorded |
| Phase not applicable17 trials | ||||||
| — | NCT07688525 | Aug → Nov 2026 expected | — | University of Sherbrooke | Not yet recruiting | No outcome recorded |
| — | NCT07598994 | Aug 2025 → Apr 2026 | temporomandibular joint disorder | Istanbul University | Completed | No outcome recorded |
| — | NCT07625475 | May 2024 → Apr 2025 | autoimmune disorder of central nervous system | University of Guelph | Completed | No outcome recorded |
| — | NCT06197529 | Nov 2023 → Mar 2024 | — | Aalborg University | Completed | No outcome recorded |
| — | NCT05560516 | Dec 2022 → Dec 2024 | chemotherapy-induced neuropathy | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| — | NCT05735626 | Jul 2021 → Dec 2023 | disorder of pharynx, stroke disorder | Hospital de Mataró | Unknown | No outcome recorded |
| — | NCT04700007 | Jan → Dec 2021 | — | Aalborg University | Completed | No outcome recorded |
| — | NCT04485689 | Jul → Dec 2020 | — | Aalborg University | Unknown | No outcome recorded |
| — | NCT03722849 | Mar 2019 → May 2022 | — | Stuart Mazzone | Completed | No outcome recorded |
| — | NCT03587220 | Aug 2018 → Aug 2019 | neuropathy, painful, sunburn | Aalborg University | Completed | No outcome recorded |
| — | NCT03146689 | Aug 2017 → Oct 2018 | osteoarthritis, knee | University of Nottingham | Completed | No outcome recorded |
| — | NCT03132142 | Apr → Aug 2017 | neurological pain disorder, skin disorder | Aalborg University | Unknown | No outcome recorded |
| — | NCT02441660 | Apr 2016 → Jul 2021 | neuropathy, painful, spinal cord injury | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| — | NCT02346916 | Oct 2013 → Aug 2015 | intermediate coronary syndrome | Bassett Healthcare | Completed | No outcome recorded |
| — | NCT02346903 | Apr 2013 → Aug 2015 | intermediate coronary syndrome | Bassett Healthcare | Completed | No outcome recorded |
| — | NCT02882555 | Jun 2012 → Dec 2013 | — | Central Hospital, Nancy, France | Completed | No outcome recorded |
| — | NCT01884116 | Mar 2011 → Mar 2012 | myofascial pain syndrome | Yonsei University | Completed | No outcome recorded |
| Comparator or background therapy25 trials | ||||||
| Phase 0 | NCT06971250 Background | May 2025 | — | Stefan Heber | Completed | No outcome recorded |
| Phase 0 | NCT03944889 Comparator | Jul 2019 → Jul 2020 | — | Toronto Rehabilitation Institute | Completed | No outcome recorded |
| Phase 0 | NCT02766517 Background | Sep 2016 → Jan 2017 | migraine disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03576508 Comparator | Jun → Sep 2018 | osteoarthritis, knee | Centrexion Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03472677 Background | Mar → Jul 2018 | osteoarthritis, knee | Centrexion Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02695745 Background | Sep 2011 → Jan 2012 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 1 | NCT00912262 Comparator | Jun → Nov 2008 | — | NeurogesX | Completed | No outcome recorded |
| Phase 1/2 | NCT01854268 Background | May 2013 → May 2014 | — | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT06807164 Comparator | Jun 2025 → Sep 2026 | neuropathy, painful | Centre Oscar Lambret | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04125563 Comparator | Jun 2019 → Jun 2022 | cough variant asthma | Vastra Gotaland Region | Completed | No outcome recorded |
| Phase 2 | NCT01393795 Comparator | Aug 2011 → Jul 2012 | pulmonary hypertension | Imperial College London | Completed | No outcome recorded |
| Phase 2 | NCT00795106 Comparator | Nov 2009 → Nov 2010 | myofascial pain syndrome | Stamford Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT00693160 Background | Dec 2007 → Oct 2010 | — | Wake Forest University | Terminated | No outcome recorded |
| Phase 3 | NCT05997979 Comparator | Mar 2024 → Jul 2028 expected | chronic pain syndrome, neuropathy, painful | University Hospital, Brest | Recruiting | No outcome recorded |
| Phase 3 | NCT03113448 Comparator | Jan → Apr 2017 | diabetic polyneuropathy | Thammasat University | Completed | No outcome recorded |
| Phase 3 | NCT02822625 Background | Aug 2016 → Jul 2019 | — | Institut de Cancérologie de Lorraine | Completed | No outcome recorded |
| Phase 3 | NCT01699854 Comparator | Aug 2012 → Sep 2013 | — | Rigshospitalet, Denmark | Terminated | No outcome recorded |
| Phase 3 | NCT01231750 Comparator | Oct 2010 → Mar 2012 | — | Neal Weintraub | Terminated | No outcome recorded |
| Phase 4 | NCT04361149 Comparator | Oct → Dec 2019 | movement disorder | Toronto Rehabilitation Institute | Completed | No outcome recorded |
| Phase 4 | NCT03124407 Comparator | Jul → Oct 2016 | osteoarthritis, knee | Propella Therapeutics | Completed | No outcome recorded |
| Phase 4 | NCT02570841 Comparator | Feb → May 2015 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00655811 Comparator | Feb → Aug 2008 | — | Wake Forest University | Completed | No outcome recorded |
| — | NCT07602387 Comparator | Mar 2024 → Mar 2027 expected | neuropathy, painful | Hospital Ambroise Paré Paris | Recruiting | No outcome recorded |
| — | NCT05059418 Comparator | Nov 2021 → Dec 2023 | burning mouth syndrome | Malmö University | Unknown | No outcome recorded |
| — | NCT01200745 Comparator | Sep 2010 → Jan 2011 | chronic pain syndrome | Kyunghee University Medical Center | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-03-15 | Chorda Pharma, Inc. | Results Top-Line Results from Clinical Trial Show Capsadyn™ Does Not Burn chordapharma.com ↗ |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-05 | Grünenthal GmbH | Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm grunenthal.com ↗ |
| 2026-02-24 | Grünenthal GmbH | Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect grunenthal.com ↗ |
| 2025-02-24 | Grünenthal GmbH | Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal grunenthal.com ↗ |
| 2025-02-24 | Apotex Inc. | Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal apotex.com ↗ |
| 2024-03-15 | Chorda Pharma, Inc. | Top-Line Results from Clinical Trial Show Capsadyn™ Does Not Burn chordapharma.com ↗ |
| 2016-12-12 | Astellas Pharma Inc | Astellas Announces Transfer of Qutenza to Grünenthal astellas.com ↗ |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 141 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | capsaicin | “A Multicenter Randomized, Double-Blind, Controlled Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Two Capsaicin Concentration Variations of NGX-1998 (10% or...” NCT01228838 ↗118“The present study will explore the efficacy of single applications of Qutenza® (capsaicin 8% patch) in reducing site pain caused by continuous SC infusion of Remodulin®, in...” NCT01393795 ↗ “It has previously been shown that a combination of tyrosine, capsaicin, catechines, and caffeine may stimulate the sympathetic nervous system and promote satiety, lipolysis and...” NCT00302276 ↗ “Qutenza (topical capsaicin 8%) is a new treatment made from chilli peppers which is applied to the skin as a patch and works directly at the nerve endings in the skin to prevent pain.” NCT01704339 ↗ “To confirm the efficacy, tolerability, and safety of NGX-4010, an 8% capsaicin dermal patch (capsaicin 640 µg/cm(2) ), in patients with postherpetic neuralgia (PHN).” PMID 21087403 ↗ Nov 2010 “5% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 5% for this study.” NCT06614608 ↗ “CGS-200-1 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 1% for this study.” NCT03528369 ↗ “Bioactive Metobes compound (green tea extract, tyrosine, caffeine and capsaicin) without calcium together with 5 mg propranolol.” NCT00302263 ↗ “QUTENZA® is a skin patch with a high concentration of capsaicin (8%) which is the component responsible for spicy peppers.” NCT02822625 ↗ “Patients received placebo vehicle or capsaicin 15 mg (Anesiva 4975) by instillation immediately prior to wound closure.” PMID 21971213 ↗ Dec 2011 “Treatment by application of capsaicin 8% (Qutenza®) patches 3 months apart (Month 1, Month 4 and Month 7).” NCT04704453 ↗ |
| Known as | 4975 | “The study drug, 4975, will be administered in various dosing regimens by intra-articular injection followed by an observation period of up to 12 weeks.” NCT00667654 ↗1“4975, highly purified capsaicin” NCT00683267 ↗ |
| Known as | 8-methyl-N-vanillyl-6-nonenamide | “The soft gel capsules used in the study are easily digested in the stomach and contain standardised doses of 0,4 mg Capsicum oleoresin with the main component capsaicin...” NCT04125563 ↗ |
| Known as | 8methylNvannilyl6nonenamide | “Capsaicin 8methylNvannilyl6nonenamide) activates TRPV1, a nonselective cation channel activated directly by heat, and low pH, and indirectly by a number of inflammatory...” NCT00771511 ↗ |
| Known as | ALGRX 4975 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00130962 ↗ |
| Known as | Anesiva 4975 | “Patients received placebo vehicle or capsaicin 15 mg (Anesiva 4975) by instillation immediately prior to wound closure.” PMID 21971213 ↗ Dec 2011 |
| Known as | ARAFARMADOL | “CAPSAICIN cream (ARAFARMADOL® ) for 8 weeks.” NCT05029297 ↗ |
| Known as | Cap | “Cap is 0.10% capsaicin alone and is an active comparator.” NCT05649228 ↗ |
| Known as | Capsaicin patch | “Capsaicin patch” NCT04238208 ↗ |
| Known as | CAPSIKA gel | “0.0125% Capsaicin gel "CAPSIKA gel"” NCT00471055 ↗ |
| Known as | CNTX-4975 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02558439 ↗ |
| Known as | NGX-1998 | “A Multicenter Randomized, Double-Blind, Controlled Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Two Capsaicin Concentration Variations of NGX-1998 (10% or...” NCT01228838 ↗1“Capsaicin Topical Liquid, NGX-1998 (10% w/w)” NCT00912262 ↗ |
| Known as | NGX-4010 | “The objective of the current open-label study was to assess the safety of repeated applications of NGX-4010, a high-concentration capsaicin patch (capsaicin 8%), over one year,...” PMID 20538187 ↗ Jun 20109“The purpose of the study is determine if an investigational drug, NGX-4010 (high-concentration capsaicin dermal patches) is effective in treating pain associated with...” NCT00061776 ↗ “The purpose of the study is to determine if an investigational drug, NGX-4010 (high-concentration capsaicin patch), is safe, tolerable and effective in treating painful...” NCT00085761 ↗ “To confirm the efficacy, tolerability, and safety of NGX-4010, an 8% capsaicin dermal patch (capsaicin 640 µg/cm(2) ), in patients with postherpetic neuralgia (PHN).” PMID 21087403 ↗ Nov 2010 “Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain.” PMID 21612836 ↗ May 2011 “NGX-4010 is a capsaicin 8% dermal patch with demonstrated efficacy in the treatment of HIV-DSP.” PMID 23351618 ↗ Jan 2013 “NGX-4010, a capsaicin 8% dermal patch” PMID 22182397 ↗ Dec 2011 |
| Known as | QUTENZA | “The present study will explore the efficacy of single applications of Qutenza® (capsaicin 8% patch) in reducing site pain caused by continuous SC infusion of Remodulin®, in...” NCT01393795 ↗15“8% Capsaicin patch [8% w/w] 640 µg/cm² of adhesive, patch area 280 cm2 (20 cm x 14 cm), (Qutenza®; capsaicin 179 mg patch, Astella Pharma Europe Ltd. Chertsey, UK)” NCT04238208 ↗ “Capsaicin patches (dosage form: patch 8% Qutenza) will be applied on 4x4 cm squared areas on the volar forearm.” NCT03587220 ↗ “Treatment by application of capsaicin 8% (Qutenza®) patches 3 months apart (Month 1, Month 4 and Month 7).” NCT04704453 ↗ “Single treatment with QUTENZA (topical capsaicin 8%)” NCT01704339 ↗ “Qutenza (capsaicin) 8% topical system” NCT04967664 ↗ “capsaicin 8% patches (Qutenza)” NCT03153813 ↗ “a capsaicin patch 8 %(Qutenza)” NCT01699854 ↗ |
| Known as | Qutenza Patch | “Treatment with Qutenza Patch (Topical Capsaicin)” NCT06744816 ↗ |
| Known as | trans-capsaicin | “OBJECTIVE: To assess the efficacy and safety of high-purity synthetic trans-capsaicin (CNTX-4975) in patients with chronic moderate-to-severe osteoarthritis (OA)-associated knee pain.” PMID 30888737 ↗ Jul 2019 |
| Known as | Zostrix | “5 mL of 0.075% capsaicin cream (Zostrix; Hi-Tech Pharmacal, Amityville, NY, USA) applied to a 5 x 10 cm target region on the lateral elbow and to bilateral C5-C6...” NCT07625475 ↗1“Participants received either a dose of 2.5 ml (75µg/ml) capsaicin cream (treatment, Zostrix brand) or skin lotion (placebo).” NCT04361149 ↗ |
| Action | Activate | “Binding of capsaicin to the vanilloid-1 receptor produces initial activation” NCT00008476 ↗ |
| Modality | Small molecule | “natural alkaloid derived from hot chili peppers” NCT00697034 ↗ |
| Route | Other | “Therapy for all groups is administered intravesically every week for 5 weeks.” NCT00004316 ↗ |
| Target | TRPV1 | “activates TRPV1” NCT00771511 ↗ |